NantPharma Receives US$125M Investment from Blackstone

NantPharma, a California-based NantWorks company whose products include high quality, biologically derived pharmaceuticals, has received a US$125m investment from Blackstone (NYSE: BX).

In conjunction with the transaction, Chinh E. Chu and Anjan Mukherjee, Blackstone Senior Managing Directors, and Arthur J. Higgins from Blackstone’s dedicated healthcare group, Blackstone Healthcare Partners, will join Dr. Patrick Soon-Shiong on the NantPharma board.

Led by Chairman Dr. Patrick Soon-Shiong, NantWorks is building an integrated evidence-based, genomically-informed, personalized approach to the delivery of care and the development of next generation diagnostics and therapeutics. NantPharma operates a number of drug manufacturing and research facilities around the country. In January 2012, it announced the acquisition and redevelopment of a former Pfizer facility in Terre Haute, Indiana, which is expected to become operational in 2015.




Join the discussion